Enbiosis Logo
Contact Us

Become a partner

Please fill out the form. We’ll be in touch as soon as possible.

Your information has been successfully sent. Thanks!



Microbiome Biomarkers
Are Used For

Wellness

*Wellness: Personalized Prebiotics
Prepared

  • Personalized Diet Engine
  • Personalized Prebiotics

Diagnostic

• Our microbiome-based liquid-biopsy product family provides non-invasive early disease detection biotech kits and software.

• AI agents discover liquid biopsy biomarkers via data-mining ENBIOSIS Biobank. Our bioscience team then translates these biomarkers into biotech products.

Scientific Research
Product Development
Prototype
Validation
Final Product
Gastrointestinal Diseases (CRC, IBS, IBD)
NAFLD
Coronary Artery Disease

Therapeutic

Long Term Products

*Therapeutic: 78% Success In Treating IBS, IBS Management Service On Sale, %83 Success In Treating Chronic Constipation

  • Disease management with microbiome diet
  • Bacteriophage therapy
  • Personal therapy solutions
  • Biotherapeutics
  • Smart microbiome transplant

ENBIOSIS MICROBIOME PLATFORM

ENBIOSIS generic framework gathers microbiome samples and lifestyle&health information by mail-in-kits or on-site from the users via a panel of applications. The samples are subject to next-generation sequencing and the data generated are placed in the biobank to be mined by AI algorithms to return the specific solutions. This generalized pipeline applicable to a range of add-on solutions sharing the same operation system.

In the background, several machine learning agents (metagenomic biomarker discoverers) constantly mine the evergrowing biobank, consisting of the sequenced data, electronic health&lifestyle records, and biological samples collected. These agents are multiple copies of AI miners searching for microbiome markers associated with human health. Their discoveries define the next-line of applications that is to use the very same service framework.

IP & COMPETITIVE LANDSCAPE

Trade Screet

In-house & Protected

Patent & Licences

Competitive Landscape

• Data-driven novel biomarkers

• SOTA non-invasive diagnostics

• Microbiome based health network supported by ENBIOSIS Biobank

• Unified platform for a spectrum of applications

Projects

New generic probiotics

Diagnosis of heart diseases based on blood microbiome

Diagnosis of gastrointestinal diseases based on gut microbiome

Diagnosis of non-alcoholic fatty liver diseases based on stool microbiome

Microbiome Medication Efficacy interaction

GMO probiotics

Stage

Phase 1

Phase 2

Phase 2 - 3

Phase 2

Phase 1

Phase 1

Vertical

Wellness

Diagnostic

Diagnostic

Diagnostic

Theurapatic

Theurapatic

Duration

Long-term

Long-term

Short-term

Short-term

Long-term

Long-term

Phase 1: Basic Study, Data Collection, Bioinformatic;
Phase 2: Wet Lab, Algo. Development;
Phase 3: Clinical Study, Certificates;
Phase 4: Sale

CLINICAL STUDIES

*The abstract of our clinical study on IBS management is now available in Gastroenterology (Impact factor 17).

We intend to expand our business by introducing new products that will be the result of an extensive research.